Bachem Holding AG

UBS upgrades Bachem Holding AG to “Buy,” citing a $78 price target amid booming peptide‑therapeutics CDMO growth—investors weigh upside potential vs. volatility.

Bachem Holding AG, a Swiss leader in peptide and oligonucleotide development, reported a 30% increase in sales and 64% jump in EBITDA in the first half of 2025, driven by strong market demand and strategic growth.